Validation of tacrolimus equation to predict troughs using genetic and clinical factors

Pharmacogenomics

Volumn 13, Issue 10, 2012, Pages 1141-1147

  Passey, Chaitali ^a   Birnbaum, Angela K ^a   Brundage, Richard C ^a   Schladt, David P ^b   Oetting, William S ^a   Leduc, Robert E ^b   Israni, Ajay K ^c   Guan, Weihua ^b   Matas, Arthur J ^d   Jacobson, Pamala A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

clearance equation; CYP3A5; kidney transplant; pharmacogenetics; pharmacokinetics; polymorphism; tacrolimus; trough; validation

Indexed keywords

TACROLIMUS;

ACCURACY; ADULT; CALCULATION; DRUG CLEARANCE; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; REVIEW; VALIDATION PROCESS;

ADULT; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 84865312250     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.98     Document Type: Review

References (32)

1. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. BMJ 320(7240), 987-990 (2000).
2. Sadée W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14(Suppl. 2), R207-R214 (2005). (Pubitemid 41631889)
3. Gage BF, Eby C, Johnson JA et al. Use of Pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
4. Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005). (Pubitemid 41510803)
5. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007). (Pubitemid 350179221)
6. Marin-Leblanc M, Perreault S, Bahroun I et al. Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics 13(1), 21-29 (2012).
7. Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
8. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011).
9. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2007).
10. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin. Pharmacother. 9(4), 635-643 (2008). (Pubitemid 351425390)
11. Vicari-Christensen M, Repper S, Basile S, Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog. Transplant. 19(3), 277-284 (2009).
12. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin. Pharmacol. Ther. 72(6), 660-669 (2002). (Pubitemid 36021005)
13. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 9(2), 130-137 (2003). (Pubitemid 36204563)
14. Tada H, Tsuchiya N, Satoh S et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant. Proc. 37(4), 1730-1732 (2005). (Pubitemid 40790812)
15. Wallemacq P, Armstrong VW, Brunet M et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 31(2), 139-152 (2009).
16. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 43(10), 623-653 (2004). (Pubitemid 38981845)
17. Laskow DA. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 62(7), 900-905 (1996). (Pubitemid 26360348)
18. Jacobson PA, Oetting WS, Brearley AM et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a Multicenter Kidney Transplant Consortium. Transplantation 91(3), 300-308 (2011).
19. Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation 87(9), 1360-1366 (2009).
20. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol. Dial. Transpl. 16(9), 1905-1909 (2001). (Pubitemid 32821425)
21. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol. 72(6), 948-957 (2011).
22. Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90(1), 68-74 (2010).
23. Gaston RS, Kasiske BL, Fieberg AM et al. Use of cardioprotective medications in kidney transplant recipients. Am. J. Transpl. 9(8), 1811-1815 (2009).
24. Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am. J. Transpl. 10(2), 315-323 (2010).
25. Jusko WJ, Piekoszewski W, Klintmalm GB et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin. Pharmacol. Ther. 57(3), 281-290 (1995).
26. Conover WJ. Practical Nonparametric Statistics (2nd Edition). Wiley, NY, USA (1980).
27. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharma. 9(4), 503-512 (1981).
28. O'Seaghdha CM, Mcquillan R, Moran AM et al. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection. Clin. Transpl. 23(4), 462-468 (2009).
29. Borobia AM, Romero I, Jimenez C et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther. Drug Monit. 31(4), 436-442 (2009).
30. Wang P, Mao Y, Razo J et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics 11(10), 1389-1402 (2010).
31. Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol. 5(3), 225-232 (1997). (Pubitemid 27489255)
32. Ralph LD, Sandstrom M, Twelves C, Dobbs NA, Thomson AH. Assessment of the validity of a population pharmacokinetic model for epirubicin. Br. J. Clin. Pharmacol. 62(1), 47-55 (2006). (Pubitemid 44195242)